Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351506 | 1.00 | CYP2E1 (0.45) | CYP2E1NR1I2HTTTP53KDM4E | |
| SCHEMBL2427730 | 0.87 | CYP2E1 (0.35) | CYP2E1NR1I2HTTTP53KDM4E | |
| SCHEMBL2427732 | 0.87 | CYP2E1 (0.35) | CYP2E1NR1I2HTTTP53KDM4E | |
| SCHEMBL14214808 | 0.81 | CYP2E1 (0.42) | CYP2E1NR1I2HTTKDM4EALDH1A1 | |
| SCHEMBL17472419 | 0.81 | CYP2E1 (0.42) | CYP2E1NR1I2HTTKDM4EALDH1A1 | |
| SCHEMBL4152499 | 0.81 | NR1I2 (0.38) | CYP2E1NR1I2 | |
| SCHEMBL4152502 | 0.81 | NR1I2 (0.38) | CYP2E1NR1I2 | |
| SCHEMBL14214916 | 0.79 | CYP2E1 (0.47) | CYP2E1NR1I2 | |
| SCHEMBL15005597 | 0.79 | NR1I2 (0.42) | CYP2E1NR1I2 | |
| SCHEMBL4346533 | 0.79 | HTT (0.39) | CYP2E1NR1I2HTTTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | CYP2E1 118/4885NR1I2 766/4885HTT 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.